Payment overview · 2025
General Payments
$352.48
12 reported records · 7 companies
Healthcare provider profile · identity verified
Alok Goyal, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Gastroenterology · SOUTH PLAINFIELD, NJ · NPI 1003848805
Verified facts
What the public records show
CMS Open Payments records show Alok Goyal, M.D. received $352.48 in general payments during 2025 across 12 reported records.
Phathom Pharmaceuticals, Inc. accounted for 35.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 35.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.09 | 18.5% | 3 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $41.33 | 11.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.77 | 10.7% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $30.93 | 8.8% | 2 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $26.99 | 7.7% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.37 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $320.21 | 11 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.18 | 2 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $41.33 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $30.93 | 2 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $26.99 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.37 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.91 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 50 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 181 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
50 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
181 | 39 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1397 | 497 |
| Amlodipine Besylate | Amlodipine Besylate | 1020 | 359 |
| Metformin Hcl | Metformin Hcl | 880 | 330 |
| Losartan Potassium | Losartan Potassium | 594 | 202 |
| Metoprolol Succinate | Metoprolol Succinate | 456 | 154 |
| Omeprazole | Omeprazole | 443 | 184 |
| Simvastatin | Simvastatin | 399 | 126 |
| Lisinopril | Lisinopril | 395 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 118 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 329 | 123 |
| Naproxen | Naproxen | 295 | 142 |
| Fluticasone Propionate | Fluticasone Propionate | 269 | 110 |
| Famotidine | Famotidine | 250 | 105 |
| Gabapentin | Gabapentin | 220 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 82 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 219 | 77 |
| Enalapril Maleate | Enalapril Maleate | 217 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 95 |
| Trulicity | Dulaglutide | 207 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 205 | 49 |
| Glimepiride | Glimepiride | 193 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 191 | 78 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 189 | 70 |
| Clopidogrel | Clopidogrel Bisulfate | 186 | 69 |
| Glipizide | Glipizide | 185 | 66 |
| Januvia | Sitagliptin Phosphate | 185 | 48 |
| Carvedilol | Carvedilol | 184 | 58 |
| Ozempic | Semaglutide | 181 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 181 | 70 |
| Azithromycin | Azithromycin | 180 | 146 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 164 | 92 |
| Metformin Hcl Er | Metformin Hcl | 158 | 48 |
| Pioglitazone Hcl | Pioglitazone Hcl | 157 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 43 |
| Amitriptyline Hcl | Amitriptyline Hcl | 148 | 61 |
| Meloxicam | Meloxicam | 142 | 56 |
| Montelukast Sodium | Montelukast Sodium | 134 | 51 |
| Eliquis | Apixaban | 129 | 33 |
| Ibuprofen | Ibuprofen | 124 | 63 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 119 | 47 |
| Promethazine Hcl | Promethazine Hcl | 116 | 89 |
| Atenolol | Atenolol | 115 | 35 |
| Furosemide | Furosemide | 112 | 49 |
| Glipizide Er | Glipizide | 110 | 38 |
| Alendronate Sodium | Alendronate Sodium | 108 | 41 |
| Humalog Kwikpen U-100 | Insulin Lispro | 104 | 31 |
| Sertraline Hcl | Sertraline Hcl | 103 | 42 |
| Finasteride | Finasteride | 101 | 34 |
| Valsartan | Valsartan | 90 | 30 |
| Clonidine Hcl | Clonidine Hcl | 85 | 31 |
| Amoxicillin | Amoxicillin | 79 | 67 |
| Meclizine Hcl | Meclizine Hcl | 69 | 33 |
| Trazodone Hcl | Trazodone Hcl | 65 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 64 | 44 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 64 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 62 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 58 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 17 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 55 | 19 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 55 | 24 |
| Alprazolam | Alprazolam | 53 | 33 |
| Jardiance | Empagliflozin | 51 | 16 |
| Prednisone | Prednisone | 51 | 35 |
| Farxiga | Dapagliflozin Propanediol | 50 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 50 | 15 |
| Bydureon Bcise | Exenatide Microspheres | 44 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 21 |
| Tramadol Hcl | Tramadol Hcl | 42 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 40 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Rybelsus | Semaglutide | 39 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | 17 |
| Spironolactone | Spironolactone | 37 | 12 |
| Fenofibrate | Fenofibrate | 36 | 13 |
| Allopurinol | Allopurinol | 35 | 17 |
| Donepezil Hcl | Donepezil Hcl | 34 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 16 |
| Methylprednisolone | Methylprednisolone | 32 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 29 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 26 | 14 |
| Hydrocortisone | Hydrocortisone | 26 | 18 |
| Lactulose | Lactulose | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 12 |
| Tradjenta | Linagliptin | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Metronidazole | Metronidazole | 23 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Mesalamine | Mesalamine | 22 | suppressed |
| Repaglinide | Repaglinide | 22 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Enulose | Lactulose | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Procto-Med Hc | Hydrocortisone | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Pregabalin | Pregabalin | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | 11 |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Enalapril-Hydrochlorothiazide | Enalapril/Hydrochlorothiazide | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fluvastatin Er | Fluvastatin Sodium | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $352.48 · 12 records | Phathom Pharmaceuticals, Inc. | BREZTRI, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, Hillrom - Carnation Ambulatory Monitor, Omnipod, Ozempic, VOQUEZNA, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error